Viva-B (02256.HK) released two preclinical research results at the ENA conference in Spain.

AASTOCKS · Oct 24 08:26

HONOR-B (02256.HK) Announces Results of Two Pre-Clinical Trials of Subsidiary Shanghai and Reputation Biomedical Technologies in Spain in October

Announced at the 36th International Conference on Molecular Targeting and Cancer Treatment (ENA) in Barcelona.

According to the above two studies, the results of the above study demonstrate the latest pre-clinical research progress of the drug “PRMT5*MTA inhibitor ABSK131” and the “oral KRASG12D small molecule inhibitor ABSK141”, respectively, in the research pipeline. (js/w)

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

和譽-B(02256.HK)附屬於西班牙ENA大會發布兩項臨床前研究結果

Viva-B (02256.HK) released two preclinical research results at the ENA conference in Spain.

Risk Disclaimer

Statement